Cargando…
Varenicline decreases alcohol consumption in heavy-drinking smokers
RATIONALE: Emerging evidence suggests that the α4β2 form of the nicotinic acetylcholine receptor (nAChR) modulates the rewarding effects of alcohol. The nAChR α4β2 subunit partial agonist varenicline (Chantix™), which is approved by the Food and Drug Administration for smoking cessation, also decrea...
Autores principales: | Mitchell, Jennifer M., Teague, Candice H., Kayser, Andrew S., Bartlett, Selena E., Fields, Howard L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438402/ https://www.ncbi.nlm.nih.gov/pubmed/22547331 http://dx.doi.org/10.1007/s00213-012-2717-x |
Ejemplares similares
-
Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers
por: Vatsalya, Vatsalya, et al.
Publicado: (2015) -
Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial
por: King, Andrea, et al.
Publicado: (2022) -
Comparative Effectiveness of Varenicline and Nicotine Replacement Therapy for Smoking Cessation in Older and Younger Smokers: A Prospective Cohort in Taiwan
por: Chang, Po-Yin, et al.
Publicado: (2019) -
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline
por: Tonstad, Serena, et al.
Publicado: (2016) -
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity
por: Ebbert, Jon O, et al.
Publicado: (2009)